Case Report: Primary Thoracic Low-Grade Fibromyxoid Sarcoma in a Young Girl Presenting With Mediastinal Mass Syndrome

Yat Chi Chan¹, Amanda N. C. Kan², Liz Y. P. Yuen³, Innes Y. P. Wan⁴, Kevin K. F. Fung⁵†, Yiu-fai Cheung⁶,⁷, Karen K. Y. Leung⁶†, Dennis T. L. Ku⁶ and Anthony P. Y. Liu⁶,⁷*,†

¹LKS Faculty of Medicine, The University of Hong Kong, Kowloon, Hong Kong SAR, China, ²Department of Pathology, Hong Kong Children's Hospital, Kowloon, Hong Kong SAR, China, ³Division of Genetic and Genomic Pathology, Department of Pathology, Hong Kong Children's Hospital, Kowloon, Hong Kong SAR, China, ⁴Department of Surgery, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China, ⁵Department of Radiology, Hong Kong Children's Hospital, Kowloon, Hong Kong SAR, China, ⁶Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Kowloon, Hong Kong SAR, China, ⁷Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Kowloon, Hong Kong SAR, China

Low-grade fibromyxoid sarcomas (LGFMSS) are typically adult-onset tumors that arise from the extremities. Here, we report an exceptional case of primary thoracic LGFMS in an 8-year-old girl that resulted in mediastinal syndrome. In reporting this case, we discuss the clinical challenges, role of molecular profiling and review reported cases of pediatric thoracic LGFMSS.

Keywords: low-grade fibromyxoid sarcoma, thoracic tumor, pediatrics, mediastinal syndrome, RNA-sequencing

INTRODUCTION

Primary thoracic tumors are infrequent in children (1). Not only do clinical features often mimic more common non-oncologic conditions and medical emergencies may also arise due to mediastinal syndrome, thereby introducing additional diagnostic and therapeutic challenges. Depending on patient age and tissue of origin, neoplastic differentials encompass pleuropulmonary blastoma (PPB), inflammatory myofibroblastic tumor, germ cell tumor, lymphoid proliferation, Ewing sarcoma and other soft-tissue sarcoma. Low-grade fibromyxoid sarcoma (LGFS) is a rare, locally aggressive malignancy that originates mainly from the proximal extremities with a median age of diagnosis of 33 years (2). Herein, we present the clinical, histologic, and molecular features for a pediatric patient diagnosed with a primary thoracic LGFMS presenting with mediastinal compression, who was successfully managed with a multidisciplinary approach and extracorporeal membrane oxygenation (ECMO) support.

CASE DESCRIPTION

A previously healthy nine-year-old girl presented with six months of cough, weight loss, and recent onset of dyspnea. Examination showed reduced air entry over the right lung, tracheal deviation to the left and facial puffiness, suggestive of superior vena cava syndrome. Subsequent X-ray and computed tomography (CT) confirmed a solid mass lesion occupying and expanding the entire right hemithorax, measuring 17 × 15 × 22 cm (Figure 1). There was total atelectasis.
Chan et al. Pediatric Thoracic Low-Grade Fibromyxoid Sarcoma

FIGURE 1 | (A) CXR and (B) CT revealed a giant mass of 16.9 cm × 15.2 cm × 22.4 cm (AP × W × H) expanding the right thorax with significant compression on the mediastinum. (C) Post-operative CT indicates partial re-expansion of the right lung.

of the right lung, expansile remodeling of the rib cage, thoracic scoliosis concaving to the right, and leftward displacement of mediastinal structure including the trachea and narrowing of the superior vena cava. Given these imaging features, Type III PPB was initially considered, with differentials including inflammatory myofibroblastic tumors and other soft-tissue sarcomas. With such extent of disease, the patient was considered to be at an extremely high risk for anesthetic procedures, core biopsy was thus done under local anesthesia, mitigating the concerns associated with use of systemic agents. Frozen section indicated the presence of spindle cells. In view of the life-threatening picture, empirical treatment for PPB according to the IV ADo regimen (ifosfamide, vincristine, doxorubicin, actinomycin) was started and the patient was monitored closely in the intensive care unit (3).

Nonetheless, reassessment CT two weeks later showed no tumor shrinkage. Histological analysis on fixed tissue obtained from core biopsy indicated abnormal spindle cells with focal myxoid areas, and absence of mitosis, necrosis or rosette formation (Figure 2). On immunohistochemistry (IHC), MUC4 positivity was detected, and fluorescence in situ hybridization study indicated the presence of FUS translocation, suggesting LGFMS (4). RNA-sequencing further confirmed the presence of FUS-CREB3L2 fusion transcript. Armed with the understanding that LGFMS is unresponsive to chemotherapy or radiotherapy, definitive surgery with a multidisciplinary team approach was undertaken one month after diagnosis. The patient had pre-operative cannulation of femoral vessels with ECMO standby and embolization of feeding vessels from the right bronchial artery (Figure 3). Endotracheal intubation was achieved without complication; medial sternotomy with right anterolateral thoracotomy (hemi-clamshell approach indicated without the need for supraclavicular incision in view of the lack of blood supply from the head and neck vessels) was then performed, followed by a successful en bloc resection of the encapsulated tumor attached to the pericardium. Intra-operatively the patient developed supraventricular tachycardia requiring cardioversion with brief internal cardiac massage. In view of borderline hemodynamic status and impaired right ventricle dysfunction during wound closure, peripheral veno-arterial ECMO (VA-ECMO) support was established. The resected specimen measured 27 × 21 × 15 cm and weighed 2793 g.

Post-operatively, the patient was maintained on VA-ECMO for two more days due to pulmonary hypertension. She was kept on ventilator for total of 6 days; her mediastinal drain was kept for 4 days, urinary catheter for 5 days and chest drains for 13 days. CT thorax with angiogram 3 weeks after surgery shown a hemodynamically insignificant segmental pulmonary embolism, which was managed with enoxaparin. Patient recovery was otherwise uneventful, with normal ventricular function as assessed by echocardiography. She was put on nocturnal oxygen 0.5 L/min for 9 months, and received intensive rehabilitation with joint input from our pediatric respirologists and physical therapists. Bimonthly serial lung function tests including lung volumes measurement and DLCO showed mild restrictive pattern. The patient had been monitored clinically and radiographically (with CT) every 4 months, remaining in remission thus far 12 months from diagnosis (Figure 1C). She was referred to the spine team for monitoring of mild scoliosis and had not required any interventions. Quality of life scores based on the PedsQL tool at 6 months from operation were 93 and 88% for psychosocial health as reported by parent and patient, respectively, and 100% in physical health by both the parent and patient.

DISCUSSION

First described in 1987, LGFMS is predominantly an adult-onset condition with less than 20% of patients presenting at less than 18 years-of-age (2, 5–7). Despite its bland histologic appearance and indolent course, the tumor remains locally aggressive and carries a small risk of distant metastasis (5). Tumor may progress over the course of decades (8). Wide local excision remains the standard-of-care, with local and distant failure rates of 9 and 6%, respectively, although these figures might be underestimations due to the propensity for late recurrence...
FIGURE 2 | (A) H&E staining on the tumor biopsy specimen – abnormal spindle cells with scattered small-sized blood vessels; focal myxoid area was noted without mitosis, necrosis or rosette formation. (B) Diffuse and strong MUC4 positive shown in the spindle cells. (C) FISH study with nuclei showing isolated green FISH signal (5’end of FUS gene) compatible with presence of FUS translocation (courtesy of Prof Ka-Fai To, Chinese University of Hong Kong). (D) RNA sequencing confirming FUS-CREB3L2 chimeric transcript.
The pathognomonic molecular driver for LGFMS was determined to be fusion between FUS and CREB3L2 (95%) or CREB3L1 (5%), while MUC4 expression represents a sensitive and specific surrogate marker on IHC studies (11–13). At the epigenomic level, LGFMS remains a molecularly distinct entity from other soft-tissue sarcomas including sclerosing epithelioid fibrosarcoma, which shares histologic similarities with LGFMS but is driven instead by EWSR1-CREB3L1/2 fusions (14). The systematic incorporation of molecular studies in the work-up of soft-tissue sarcoma has become indispensable for the prompt and precise classification of tumor type.

Whilst pulmonary metastasis is the commonest mode of distant spread, primary intra-thoracic LGFMS have only been anecdotally reported (7, 15–21). These unusual lesions have been described to arise from the pleura, lung parenchyma, and mediastinum. In our patient, the intraoperative findings suggested a pericardial origin of the tumor. In the pediatric age group, Steiner and colleagues reported on a 12-year old girl with a 23 cm intrathoracic LGFMS that appeared to arise from the posterior thoracic wall without mediastinum invasion, was surgically treated uneventfully (19), whereas a 15-year old boy with a 3 cm thoracic lesion was described as part of the French Sarcoma Group experience (5). As part of Children’s Oncology Group ARST0332 cohort of non-rhabdomyosarcoma soft-tissue sarcoma, one 12-year old boy with intrapulmonary LGFMS without mass effect shown in axial CT thorax was reported (7). Our patient likely represents the youngest reported individual with thoracic LGFMS in the literature. Of note, the splaying of ribs and scoliosis present in our patient are evidence for chronicity suggesting an even earlier onset of our patient’s tumor.

Mediastinal mass syndrome (MMS) as a result of neoplastic growth represents an oncologic emergency, which can manifest as life-threatening cardiovascular decompensation as a result of mass effects on the surrounding anatomical structures (22, 23). According to previous publications, patients have higher risk of acute cardiovascular decompensation if they present with orthopnea, stridor, wheeze, shortness of breath, syncope, and upper body edema; most of which were present in our patient (24, 25). Radiological assessment including CT thorax and echocardiogram is recommended to facilitate risk assessment prior to sedation and interventions. Prior to any treatment, it is important to maintain spontaneous respiration, avoid sedation, avoid neuromuscular blocking agents, and preload augmentation by optimizing the fluid status and pharmacologic support (24). Corticosteroid is of value mainly in lymphoid malignancies although close monitoring for resultant tumor lysis syndrome is essential. Timely transferal to a tertiary referral center with experience in cardiothoracic surgery and mechanical circulatory support is key in preventing catastrophic cardiorespiratory decompensation. Our case also demonstrated that ECMO can be successfully used in pediatric patients with massive mediastinal mass as a cardiovascular support modality during surgical treatment, for which there is only a limited number of pediatric case reports (26, 27). Multi-disciplinary input is essential to facilitate tumor resection and to minimize morbidity and mortality. Beyond the acute phase, pulmonary rehabilitation is key to ensure the patient’s long-term well-being and functional outcome, alongside radiographic surveillance which remains essential in order to monitor potential disease recurrence.

CONCLUSION

We present the clinical course and molecular finding of a rare case of pediatric thoracic LGFMS. Molecular profiling facilitates the classification and management of uncommon soft-tissue tumors while pre-emptive multi-modal measures are integral to the successful management of patients with mediastinal syndrome.

DATA AVAILABILITY STATEMENT

The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.
AUTHOR CONTRIBUTIONS

YC, DK, and AL: conceptualizing and initial drafting. YC, AK, LY, and AL: data collection. DK and AL: supervision. All authors contributed to the patient care, critical review, and final approval.

REFERENCES

1. Lichtenberger JP 3rd., Biko DM, Carter BW, Pavio MA, Huppmann AR, Chung EM, et al. Primary lung tumors in children: radiologic-pathologic correlation from the radiologic pathology archives. *RadioGraphics*. (2018) 38:2151–72. doi: 10.1148/rg.20181810192

2. Mohamed M, Fisher C, Thway K. Low-grade fibromyxoid sarcoma: clinical, morphologic and genetic features. *Ann Diagn Pathol*. (2017) 28:60–7. doi: 10.1016/j.anndiagpath.2017.04.001

3. Bisogno G, Brennan B, Orbach D, Stachowicz-Stencel T, Cecchetto G, Indolfi P, et al. Treatment and prognostic factors in pleuropulmonary blastoma: an EXPERT report. *Eur J Cancer*. (2014) 50:178–84. doi: 10.1016/j.ejca.2013.08.015

4. Doyle LA, Möller E, Cin PD, Fletcher CDM, Mertens F, Hornick JL, et al. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. *Am J Surg Pathol*. (2011) 35:733–41. doi: 10.1097/PAS.0b013e318205bc68

5. Guilou L, Benhattar J, Gengler C, Gallagher G, Ranchère-Vince D, Collin F, et al. Translocation-positive Low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French sarcoma group. *Am J Surg Pathol*. (2007) 31:1387–402. doi: 10.1097/PAS.0b013e3180321959

6. Evans HL. Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptive benign appearance. *Am J Clin Pathol.* (1987) 88:615–9. doi: 10.1093/ajcp/88.5.615

7. Sargar K, Kao SC, Spunt SL, Hawkins DS, Parham DM, Coffin C, et al. MR and CT imaging of low grade Fibromyxoid sarcoma in children: a report from Children’s oncology group study ARST0332. *AJR Am J Roentgenol.* (2015) 205:414–20. doi: 10.2214/AJR.14.13972

8. Lam YL, Ho WY, Ng TP, Kan A, Shek TWH. A sarcoma of 23 years’ duration: symptom duration is not a reliable parameter to exclude malignancy. *Hong Kong Med J.* (2012) 18:250–2.

9. Folpe AL, Lane KL, Paul G, Weiss SW. Low-grade fibromyxoid sarcoma and hyaline-vascular spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. *Am J Surg Pathol.* (2000) 24:1353–60. doi: 10.1097/00000478-200010000-00004

10. Evans HL. Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up. *Am J Surg Pathol.* (2011) 35:1450–62. doi: 10.1097/PAS.0b013e318225687

11. Panagopoulos I, Storlazzi CT, Fletcher CDM, Fletcher JA, Nascimento A, Domanski HA, et al. The chimeric FUS/CREBL2 gene is specific for low-grade fibromyxoid sarcoma. *Genes Chromosomes Cancer*. (2004) 40:218–28. doi: 10.1002/gcc.20037

12. Mertens F, Fletcher CDM, Antonescu CR, Coidre JM, Colechia M, Domanski HA, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREBL1 fusion gene. *Lab Invest.* (2005) 85:408–15. doi: 10.1038/labinvest.3700630

13. Möller E, Hornick JL, Magnusson L, Veerla S, Domanski HA, Mertens F, et al. FUS-CREBL2/L1-positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1. *Clin Cancer Res*. (2011) 17:2646–56. doi: 10.1158/1078-0432.CCR-11-0145

14. Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, et al. Sarcoma classification by DNA methylation profiling. *Nat Commun.* (2012) 429:498. doi: 10.1038/41467-020-20603-4

15. Jakowski JD, Wakely PE Jr. Primary intrathoracic low-grade fibromyxoid sarcoma. *Hum Pathol.* (2008) 39:623–8. doi: 10.1016/j.humpath.2007.08.017

16. Perez D, El-Zammar O, Cobanov B, Naous R. Low-grade fibromyxoid sarcoma: a rare case in an unusual location. *SAGE Open Med Case Rep.* (2020) 8:2050313x20944315. doi: 10.1177/2050313X20944315

17. Liang W, Xu S. Imaging findings from a case of pleural low-grade fibromyxoid sarcoma similar to mesothelioma with pleural effusion. *Clin Respir J*. (2016) 10:120–4. doi: 10.1111/crj.12175

18. Maeda E, Ohta S, Watanishi T, Goto A, Nakajima A, Ohtomo K, et al. Imaging findings of thoracic low-grade fibromyxoid sarcoma: report of three cases. *Jpn J Radiol*. (2009) 27:375–80. doi: 10.1111/j.1600-0939-0351-2

19. Steiner MA, Giles HW, Daley WP. Massive low-grade fibromyxoid sarcoma presenting as acute respiratory distress in a 12-year-old girl. *Pediatr Radiol*. (2009) 39:396–9. doi: 10.1007/s00247-008-0694-1

20. Higuchi M, Suzuki H, Shio Y, Hoshi S, Gotoh M. Successfully resected intrathoracic low-grade fibromyxoid sarcoma. *Gen Thorac Cardiovasc Surg*. (2010) 58:348–51. doi: 10.11178/s091774-009-0534-x

21. Tominaga Y, Eguchi T, Shina T, Hamanaka K, Amano J, Asaka S, et al. An intrathoracic low-grade fibromyxoid sarcoma arising from the chest wall with massive pleural effusion. *Ann Thoracic Cardiovasc Surg*. (2014) 20:509–12. doi: 10.5761/atxsr.12.02196

22. Leung KKY, Hon KL, Hui WF, Leung AK, Li CK. Therapeutics for paediatric oncological emergencies. *Drugs Context*. (2020) 2020–11–5. doi: 10.7573/dic.2020–11–5

23. Wickiser JE, Thompson M, Leavey PJ, Quinn CT, Garcia NM, Aquino VM, et al. Extracorporeal membrane oxygenation (ECMO) initiation without intubation in two children with mediastinal malignancy. *Pediatric Blood Cancer*. (2007) 49:751–4. doi: 10.1002/pbc.20741

24. Leung KKY, Ku SW, Hon KL, Chigaru L, Chiang AKS, Kan EYL, et al. Recommendations on the management of interhospital transport of pediatric patients with mediastinal mass. *Pediatr Emerg Care*. (2021) 38:e1104–11. doi: 10.1097/PEC.0000000000002517

25. Stricker PA, Gurnaney HG, Litman RS. Anesthetic management of children with an anterior mediastinal mass. *J Clin Anesth*. (2010) 22:159–63. doi: 10.1016/j.jcaan.2009.10.004

26. Leow L, Sampath HK, Yong KJ, Kofidis T, Tam JKC, MacLaren G, et al. Rescue extracorporeal membrane oxygenation. *J Artif Organs*. (2021) 24:450–7. doi: 10.1007/s10047-021-01264-6

27. Frey TK, Chopra A, Lin RJ, Levy RJ, Gruber P, Rheingold SR, et al. A child with anterior mediastinal mass supported with veno-arterial extracorporeal membrane oxygenation. *Pediatr Crit Care Med*. (2006) 7:479–81. doi: 10.1097/01.PCC.0000235247.10888.F8

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chan, Kan, Yuan, Wan, Feng, Cheung, Leung, Ku and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.